 | This articlecontainspromotional content. Please helpimprove it by removingpromotional language and inappropriateexternal links, and by adding encyclopedic text written from aneutral point of view.(April 2021) (Learn how and when to remove this message) |
 | |
| Company type | Public |
|---|---|
| Nasdaq: BLRX TASE: BLRX | |
| Industry | Biotechnology |
| Founded | 2003; 22 years ago (2003) |
| Headquarters | , Israel |
Key people | Philip Serlin (CEO) |
| Services | Drug development |
| Owners | Novartis (12.8%, 2014) |
| Website | www |
| Footnotes / references [1][2] | |
BioLineRx Ltd. (Hebrew:ביוליין אר אקס), orBioLine, is apublicly traded drug development company. Headquartered in Israel, its shares are traded on theNASDAQ Capital Market and on theTel Aviv Stock Exchange.
The firm was established in 2003 as a joint venture ofTeva, Hadasit Bio-Holdings, theJerusalem Development Authority, Yehuda Zisapel, and other investors.[3] It executed aninitial public offering on the Tel Aviv Stock Exchange in February 2007, raising 211 millionNIS ($50 million) – the TASE's largest biotech IPO until that time.[4][5] In July 2011 BioLine'sADRs began trading on the NASDAQ Capital Market.[6][7] In January 2012, the firm announced a deal with Genoscience, a French pharmaceutical company to jointly develop and market the BL-8020 compound, as a treatment forHepatitis C.[8] At the end of 2014,Novartis acquired a 12.8%stake in the company as a strategic move to gain access to Israeli-sourced drug candidates.[2]
Morris Laster, (M.D.) an alumnus of.Downstate Medical Center, wasCEO of BioLineRx until 2009. He was replaced by Kinneret Savitsky, alumnus ofTel Aviv University early in 2010.[9] Savitsky was replaced as CEO by BioLine COO Philip Serlin on October 10, 2016.
BioLineRx is a drug development company When promising compounds are discovered, the firm leads them throughpreclinical trials and engages other companies to further develop them into commercializable drugs.[10] The company entered into its first major commercialization agreement in 2009 when it partnered with Ikaria Holdings Inc. to develop its BL-1040 compound.[11] In 2010, BioLine entered into a commercialization agreement with Cypress Bioscience Inc. for development of its BL-1020 compound. The agreement with Cypress was canceled in 2011 when the company was taken over byRamius LLC.[12]
Below is a partial list of drug compounds in various stages ofdevelopment byBioLineRx. Unless indicated otherwise, they have not obtained regulatory approval in relation to the diseases cited.
Bioline Therapeutics today pulled off its initial public offering in Tel Aviv, raising NIS 211 million at a company valuation of NIS 494 million, making this the biggest flotation by a biotechnology company in local history.
BioLineRx Ltd. on Wednesday priced the largest ever initial public offering of a biomedical company on the Tel Aviv Stock Exchange, raising a total of NIS 211 million, or $50m.
| Healthcare | |
|---|---|
| Communication & Networks | |
| Software | |
| Electronics | |
| Security & defense | |
| Consumer goods | |
| Conglomerates | |
